Axovant Sciences’ (AXON) Sell Rating Reiterated at Chardan Capital
Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “sell” rating restated by stock analysts at Chardan Capital in a research report issued to clients and investors on Thursday. They currently have a $8.00 price objective on the biotechnology company’s stock. Chardan Capital’s target price points to a potential downside of 59.66% from the stock’s previous close.
A number of other equities research analysts have also recently commented on AXON. Evercore ISI initiated coverage on Axovant Sciences in a research note on Friday, September 8th. They set an “outperform” rating and a $30.00 target price on the stock. Oppenheimer Holdings, Inc. lifted their target price on Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. CIBC lifted their target price on Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. Cowen and Company reiterated an “outperform” rating and set a $30.00 target price (up from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a research note on Friday, June 9th. Four research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $26.05.
Axovant Sciences (AXON) traded down 2.42% during trading on Thursday, hitting $19.35. 509,093 shares of the company’s stock traded hands. The company’s 50 day moving average price is $20.75 and its 200 day moving average price is $15.14. The company’s market cap is $2.08 billion. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $21.85.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.12). Analysts expect that Axovant Sciences will post ($2.36) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Axovant Sciences’ (AXON) Sell Rating Reiterated at Chardan Capital” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/axovant-sciences-axon-sell-rating-reiterated-at-chardan-capital.html.
A number of hedge funds have recently bought and sold shares of AXON. Bank of America Corp DE grew its holdings in Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Axovant Sciences by 1.5% during the 3rd quarter. Wells Fargo & Company MN now owns 8,130 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 117 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Axovant Sciences during the 2nd quarter valued at about $128,000. Royal Bank of Canada grew its holdings in Axovant Sciences by 467.6% during the 2nd quarter. Royal Bank of Canada now owns 10,500 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 8,650 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Axovant Sciences during the 4th quarter valued at about $139,000.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.